Transferring the concept of multinuclearity to ruthenium complexes for improvement of anticancer activity. - Wikidata - wikimedia - TriplyDB

Transferring the concept of multinuclearity to ruthenium complexes for improvement of anticancer activity.

Transferring the concept of multinuclearity to ruthenium complexes for improvement of anticancer activity.

http://www.wikidata.org/entity/Q33640724

about

Bifunctional polypyridyl-Ru(II) complex grafted onto gadolinium-based nanoparticles for MR-imaging and photodynamic therapy.A Family of Potent Ru(II) Photosensitizers with Enhanced DNA Intercalation: Bimodal Photokillers.Organometallic anticancer compounds Ruthenium- and Osmium-Arene Complexes of 2-Substituted Indolo[3,2-c]quinolines: Synthesis, Structure, Spectroscopic Properties, and Antiproliferative Activity.Coordination Driven Self-Assembly and Anticancer Activity of Molecular Rectangles Containing Octahedral Ruthenium Metal Centers.Transferrin as a model system for method development to study structure, dynamics and interactions of metalloproteins using mass spectrometry Kinetic and mechanistic study on the reactions of ruthenium(ii) chlorophenyl terpyridine complexes with nucleobases, oligonucleotides and DNA.Regulating the anticancer properties of organometallic dendrimers using pyridylferrocene entities: synthesis, cytotoxicity and DNA binding studies.Aqueous chemistry and antiproliferative activity of a pyrone-based phosphoramidate Ru(arene) anticancer agent.Palladium(II) complexes with N-heteroaromatic bidentate hydrazone ligands: the effect of the chelate ring size and lipophilicity on in vitro cytotoxic activity.Ruthenium-Arene-β-Carboline Complexes as Potent Inhibitors of Cyclin-Dependent Kinase 1: Synthesis, Characterization and Anticancer Mechanism Studies.Identification of the structural determinants for anticancer activity of a ruthenium arene peptide conjugate.[Au2(phen(2Me))2(μ-O)2](PF6)2, a Novel Dinuclear Gold(III) Complex Showing Excellent Antiproliferative Properties.Synthesis, characterisation and in vitro anticancer activity of hexanuclear thiolato-bridged arene ruthenium metalla-prisms.Cationic arene ruthenium(II) complexes with chelating P-functionalized alkyl phenyl sulfide and sulfoxide ligands as potent anticancer agents.The influence of RAPTA moieties on the antiproliferative activity of peripheral-functionalised poly(salicylaldiminato) metallodendrimers.Anticancer activity of hydrogen-bond-stabilized half-sandwich Ru(II) complexes with heterocycles.The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials.Arene ruthenium complexes as anticancer agents.Maltol-derived ruthenium-cymene complexes with tumor inhibiting properties: the impact of ligand-metal bond stability on anticancer activity in vitro.Organometallic cis-Dichlorido Ruthenium(II) Ammine Complexes.New dinuclear ruthenium arene complexes containing thiosemicarbazone ligands: synthesis, structure and cytotoxic studies.Quadruplex DNA-Stabilising Dinuclear Platinum(II) Terpyridine Complexes with Flexible Linkers.Structure-activity relationships for ruthenium and osmium anticancer agents - towards clinical development.Aminophosphine ligands as a privileged platform for development of antitumoral ruthenium(ii) arene complexes.Synthesis, Characterization, and Biological Studies of New Ruthenium Polypyridyl Complexes Containing Noninnocent Ligands

P2860

Q30655635-EBCF4D42-9B42-48F4-9375-3CAAA9522641 Q30977137-9BBDC66D-21D6-416A-A09C-D3CF201C5958 Q34476685-1497250A-F0A7-44F7-9075-249F20C2C147 Q34498243-3A87C13B-6D22-4715-9DBE-BAEA18514CA4 Q35110527-FE3E09C2-DFE4-4F56-9DF9-C66246CB3F10 Q35511065-E44652DE-70B2-4814-8961-1FD932718AA5 Q38289233-8ECFA405-456E-4AA1-B82B-14204ECA666E Q38770155-D0DAA324-9DC2-4E0A-9ABC-8328B9A942DE Q38990666-FFB9FFEF-B0E5-43B8-AC3E-06D203D5FCE4 Q39014722-988934F1-DD66-4574-94C3-1F15E1D610F1 Q39121561-DE9B1E6B-16B0-4AE7-B48E-E6A1F9E78C69 Q39146826-28247D7A-4AB1-461A-B253-0E9177CE1B55 Q39159067-3D7985C6-B487-4C83-93A0-0D4AFBE77747 Q39205740-8E127F06-D846-4BB4-BD30-C938E9A91E1B Q39206559-2856AEA3-5551-47C2-9A13-AC391D97C893 Q39246566-56841CBC-2431-4482-A81E-9EAFD43F3C94 Q39295179-5A13844B-13C0-4310-8D2D-2CC03A5F22BB Q39400527-60C15B63-6D07-4BED-862A-21FC84787565 Q39706669-DFCBA6E2-DBC0-4732-A9BF-4D6219DBAC0D Q39788647-DFE35D51-A1B7-4F4B-82FB-92AD96D57C19 Q42555974-3ABD9331-9E02-463A-A591-C3A21DC797ED Q44868326-9C87F21B-321D-45FC-9E36-6B12147D7DF8 Q48044781-CA4A97DE-9A22-4212-AED1-C904E6B3FE42 Q49687144-7A9AABBA-B786-4FA2-9AD3-F959599990E3 Q50073136-360C2D40-556C-47E6-8E61-0F4CCDBC9BC5 Q58996797-404F523E-5A78-4E26-9A9F-BA6BB8768727

P2860

Transferring the concept of multinuclearity to ruthenium complexes for improvement of anticancer activity.

http://www.wikidata.org/entity/Q33640724

description

2009 nî lūn-bûn

@nan

2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Transferring the concept of mu ...... vement of anticancer activity.

@ast

Transferring the concept of mu ...... vement of anticancer activity.

@en

type

label

Transferring the concept of mu ...... vement of anticancer activity.

@ast

Transferring the concept of mu ...... vement of anticancer activity.

@en

prefLabel

Transferring the concept of mu ...... vement of anticancer activity.

@ast

Transferring the concept of mu ...... vement of anticancer activity.

@en

P1433

Q33640724-5241FDF4-9EFB-4C68-BBA0-75AF61476792

P1476

Q33640724-E1E73CBC-9C3E-4203-B02C-3F5EC5F62A29

P2093

Q33640724-05E4786D-647D-41C6-9C97-8A67BC2BCA22

Q33640724-0E620F88-5EB1-432F-824C-E7E4BE85C3B4

Q33640724-0FF6C09E-D25E-4560-BB82-89F3A7CA6B92

Q33640724-14237612-1A86-4050-A5D7-1ED8AE873E6B

Q33640724-34880A8F-6448-465A-B7BA-0DC93AF6EC81

Q33640724-60E317C4-9251-4F58-8022-30EBA6DD210A

Q33640724-C48CF639-90DC-4D14-8939-DC61FDB2904B

Q33640724-C8BDCA8F-5F6B-41FD-8E5C-719F2ADE5C46

Q33640724-D873EECE-04B4-4B43-A93D-5B1B56B27BBF

Q33640724-FF0929B0-54C4-403E-B717-59C816C593D7

P2860

Q33640724-0286F8DF-BA1E-4602-ADEA-0E204CE695AD

Q33640724-1AEA0472-E328-485B-8D9B-F66A76C1348A

Q33640724-1D3D9EE4-E4CB-4DFC-BCDD-3F62E2F20A87

Q33640724-1DB33008-CB20-413C-979C-A1CDB08BFF09

Q33640724-218091A9-8951-480E-A778-E39DCB1A83E0

Q33640724-2605629D-2DA4-4917-AB04-FA530F8A5BCE

Q33640724-2D7CCAEA-2C68-4A0B-B76A-5A7F7026C67D

Q33640724-31338D62-8030-41C6-8741-2DCE4DFACBEB

Q33640724-3368BC09-C887-4C33-A91B-9DC24579F898

Q33640724-4A249117-957B-435C-877B-F32157B5BA00

P304

Q33640724-794760A1-EAF8-45C0-B338-9D2BF3850A12

P31

Q33640724-644BFDFB-C3EB-4981-9D5D-DD85084EBE4D

P356

Q33640724-4FBEFC25-3C59-415D-969D-6CFBF7E3D324

P407

Q33640724-8B3C836B-B85A-48AF-B473-77EE8A37A9F2

P433

Q33640724-83FE41A9-FE80-4AD8-A0FD-2F9930DE64EA

P478

Q33640724-2C2EF3FB-7CFB-407C-9240-7AC9BA4BFDAD

P50

Q33640724-21B38300-C174-4F63-8396-73E972B9F13D

Q33640724-4A4F8BA8-6119-49F0-95D3-0A973775E5EA

Q33640724-7B7BBDA8-7964-41E1-8459-72E914C2C05E

Q33640724-86BECFC2-3335-451D-9D36-97761257E096

Q33640724-9456EF5C-4192-4A13-A513-F399CFEDBF2F

P577

Q33640724-403C0E63-D216-4669-B089-61AA140EF333

P5875

Q33640724-EEF2B08C-C21A-45C2-829C-B79B2BD0205A

P698

Q33640724-58E7C89E-4BC6-449A-B3B9-0EBD92E4941D

P932

Q33640724-44CAD0EF-537A-4305-8C04-83A587ED8DB8

P356

P1433

Journal of Medicinal Chemistry

P1476

Transferring the concept of mu ...... vement of anticancer activity.

@en

P2093

Alexander E Egger

http://www.w3.org/2001/XMLSchema#string

Franz Klein

http://www.w3.org/2001/XMLSchema#string

John B Mangrum

http://www.w3.org/2001/XMLSchema#string

Kay Severin

http://www.w3.org/2001/XMLSchema#string

Magdalena Maruszak

http://www.w3.org/2001/XMLSchema#string

Marco A Mendoza

http://www.w3.org/2001/XMLSchema#string

Maria G Mendoza-Ferri

http://www.w3.org/2001/XMLSchema#string

Nicholas P Farrell

http://www.w3.org/2001/XMLSchema#string

Patrick J Bednarski

http://www.w3.org/2001/XMLSchema#string

Rene E Eichinger

http://www.w3.org/2001/XMLSchema#string

P2860

A rapid alkaline extraction procedure for screening recombinant plasmid DNA

A formula for correlating pKa values determined in D2O and H2O.

Correlations between the activities of 19 anti-tumor agents and the intracellular glutathione concentrations in a panel of 14 human cancer cell lines: comparisons with the National Cancer Institute data.

Studies on the reactivity of organometallic Ru-, Rh- and Os-pta complexes with DNA model compounds.

Ruthenium porphyrin compounds for photodynamic therapy of cancer.

Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesophageal adenocarcinoma.

From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A).

New metal complexes as potential therapeutics.

Transferrin: structure, function and potential therapeutic actions.

Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches.

P304

916-925

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/JM8013234

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P50

Christian Hartinger

Michael A. Jakupec

Bernhard K. Keppler

Alexey A. Nazarov

Michael Groessl

P577

2009-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23949740

http://www.w3.org/2001/XMLSchema#string

P698

19170599

http://www.w3.org/2001/XMLSchema#string

P932

2819033

http://www.w3.org/2001/XMLSchema#string